BRIEF published on 06/28/2024 at 07:35, 1 year 5 months ago H.C. Wainwright & Co. Initiates MedinCell’s Coverage with "Buy" Recommendation FDA Approval BUY Rating Biopharmaceuticals H.C. Wainwright & Co. Medincell
PRESS RELEASE published on 06/28/2024 at 07:30, 1 year 5 months ago Inside Information / Other news releases H.C. Wainwright & Co. initiates coverage of MedinCell with a 'Buy' recommendation at €24 price target, reflecting +80% potential increase. MedinCell achieves milestones with FDA approvals, positive Phase 3 results, and collaboration with AbbVie FDA Approval Coverage Initiation H.C. Wainwright & Co. Medincell Pharmaceutical Sector
BRIEF published on 06/11/2024 at 09:05, 1 year 5 months ago Medincell Joins Euronext Tech Leaders Index Innovation Tech Sector Investor Visibility Medincell Euronext Tech Leaders
PRESS RELEASE published on 06/11/2024 at 09:00, 1 year 5 months ago Inside Information / Other news releases Medincell joins Euronext Tech Leaders, gaining access to a broad investor base and support services. CEO Christophe Douat highlights the company's growth and tech innovation leadership Tech Sector Financial Strategy Investor Base Medincell Euronext Tech Leaders
BRIEF published on 05/10/2024 at 18:05, 1 year 6 months ago Medincell announces details on capital and voting rights in accordance with regulations Euronext Paris Share Capital Voting Rights Financial Regulation Medincell
BRIEF published on 05/08/2024 at 12:35, 1 year 6 months ago Positive Results for the SOLARIS Phase 3 Trial of Olanzapine Schizophrenia Medincell SOLARIS Olanzapine TEV-'749
PRESS RELEASE published on 05/08/2024 at 12:30, 1 year 6 months ago Inside Information / Other news releases Teva and Medincell announce positive Phase 3 efficacy results from SOLARIS trial evaluating TEV-'749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia Schizophrenia Medincell Teva Phase 3 Efficacy Results SOLARIS Trial
BRIEF published on 05/08/2024 at 09:05, 1 year 6 months ago Medincell Temporarily Suspends its Euronext Paris Listing Euronext Paris Press Release Financial Markets Medincell Share Suspension
PRESS RELEASE published on 05/08/2024 at 09:00, 1 year 6 months ago Inside Information / Other news releases Medincell suspends listing of shares on Euronext Paris pending press release. Innovative biopharmaceutical company developing long-acting injectable drugs Euronext Paris Biopharmaceutical Suspension Medincell Long-acting Injectable Drugs
Published on 12/05/2025 at 02:35, 3 hours 50 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 25 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 20 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 25 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 54 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 34 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 59 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 9 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 14 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 25 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 40 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 40 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 24 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
